Kite Submits sBLA to FDA for Yescarta in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
Kite, a Gilead Company announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Yescarta (axicabtagene…
Read More...
Read More...
